Swiss-Based Biotech Company Hedera Dx Has Raised Euro 15 Million Series A

Led by Tommi Lehtonen(CEO & Co-Founder), Christian Meisel(CMO & Co-Founder), Damien Lapray(CCO & Co-Founder), Kaarlo Haikonen(Director Engineering & Product), Sanga Mitra Boppudi(Director Assay Development, PhD.), Thomas Vetterli(Director Bioinformatics & ML), Paola Castelli(Vice President of Sales), & Frances Rhodius Sagnier(Director of Finance & Operations), Hedera Dx has raised Euro 15 Million Series A led by Vsquared Ventures with participation from another new investor Tesi and existing backers Helsana HealthInvest, Eyrir Venture Management, Inventure and Top Harvest to drive advanced cancer care.

The funding will advance Hedera Dx’s mission to break down structural barriers limiting access to targeted cancer therapies. Led by founders with deep experience scaling leading European genetics and healthcare companies—including Blueprint Genetics, Roche, and Molecular Health—Hedera Dx is now focused on building the next global healthcare leader.

Founded in 2021, Hedera Dx has developed liquid biopsy solutions that enable cost-effective, in-house cancer testing. Combining affordability with exceptional quality, the technology is already in use across 11 European countries. Alongside advanced molecular profiling to guide treatment decisions, Hedera Dx’s AI-native platform also extracts patient-centric insights from real-world data to accelerate the development of next-generation oncology therapies.

The Series A funding will drive commercial growth and enhance Hedera Dx’s real-world data infrastructure to serve the global oncology market.